Drawing for LIVITECH

USPTO serial 79329443

LIVITECH

Reviewed by CopyMark Law Group

Reg. 7033146Status 700Registered
Filing date
Status date
Registration date
Apr 25, 2023
Examiner
MCGILL, CIERRA L
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with LIVITECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ronald M. Kachmarik

Ronald M. Kachmarik Cooper Legal Group, LLC1388 Ridge Road, Unit 1Hinckley, OH 44233UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents for chemical analyses for scientific use; reagents for scientific use; reagents for scientific or medical research use; diagnostic reagents for scientific use; reagents for immunoserology and molecular diagnosis for research use; chemical reagents for genetic research; in-vivo diagnostic reagents for scientific use; diagnostic reagents for scientific use or for research use; diagnostic reagents for in-vitro use in biochemistry, molecular biology, clinical chemistry and microbiology for research use; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the publicACTIVE—
005Pharmaceuticals for use in human or veterinary medicine, for scientific use for the treatment of inflammatory diseases and liver diseases; chemical preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; biological preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; preparations for use in human or veterinary medicine, or for pharmaceutical use, namely, for the treatment of inflammatory diseases and liver diseases; microorganism cultures for use in human or veterinary medicine, or for pharmaceutical use; cell preparations for use in human or veterinary medicine, or for pharmaceutical use, in particular for gene therapy and cell therapy, namely, cell growth media; blood and blood derived samples, namely, plasma, serum, platelet free samples for medical use; diagnostic biomarker reagent products for use in human or veterinary medicine; diagnostic reagents for use in human or veterinary medicine; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the publicACTIVE—
009Downloadable software for use in diagnosis of inflammatory diseases and liver diseases; downloadable software applications for use in diagnosing medical conditions; scientific apparatus and instruments especially for recording, processing, reproducing, transmitting data, namely, electronic data loggers and recorders; data processing equipment; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the publicACTIVE—
010Medical apparatus, instruments and equipment, namely, DNA, RNA and protein analysis apparatus, DNA, RNA and protein quantifiers, medical devices for measuring DNA, RNA, biochemical and physical parameters, namely, concentration of biomarkers relating to the evaluation of inflammatory and liver diseases and blood analyzers for evaluation of inflammatory and liver diseases; instruments and tools for medical diagnosis, namely, computer displays and computer monitors and controllers therefor used in direct association with medical diagnosis apparatus during the process of diagnosis of a condition in an individual; diagnostic apparatus for medical use, namely, medical diagnostic apparatus for testing the biomarker levels; all these goods exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the publicACTIVE—
042Pharmaceutical research, namely, research for the discovery of new medicines; scientific research, especially in the medical, biomedical, chemical, genetic, pharmaceutical field; basic and applied scientific research; technical scientific research; scientific research, namely, sorting and selection of molecules; scientific research services, namely, development and validation of biological tests, cellular tests and genetic tests; scientific research, namely, functional genomics for identifying, characterizing, validating and developing biologically active molecules; analysis of biological substances in biological fluids; computer programming in the field of scientific research and for the pharmaceutical industry; engineering services, namely, surveying; technical project study being scientific research; professional consultancy unrelated to business dealings in the field of scientific and medical research; research and development of new pharmaceutical products for others; scientific research in the field of pharmacy; all these services exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the publicACTIVE—
044Medical analysis relating to the diagnosis and treatment of persons and medical diagnosis services in inflammatory diseases and liver diseases; medical analyses of blood samples, biological preparations and biological fluids relating to the diagnosis and treatment of persons; support services in the field of medicine, health care and pharmaceutical research, namely, medical analysis for the diagnosis and treatment of patients; medical information; provision of medical information; all these services exclusively in the field of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases; and none of them related to telemedicines services, online medical consultation and online medical assistance provided to the publicACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 19, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 28, 2023FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 3, 2023FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 3, 2023FIMPFINAL DISPOSITION PROCESSED—
Jul 25, 2023FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 25, 2023NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 25, 2023R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 7, 2023GPNXNOTIFICATION PROCESSED BY IB—
Feb 7, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 7, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 18, 2023OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 18, 2023OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jan 18, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 17, 2023DOCKASSIGNED TO EXAMINER—
Dec 31, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 31, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Dec 31, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 31, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 31, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 27, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 27, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 24, 2022TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 24, 2022CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 24, 2022TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 16, 2022RFNTREFUSAL PROCESSED BY IB—
Apr 28, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 28, 2022RFRRREFUSAL PROCESSED BY MPU—
Mar 18, 2022RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 17, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 17, 2022DOCKASSIGNED TO EXAMINER—
Jan 7, 2022MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 3, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 23, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance